Evidence map›Paper›PMID 25528757›Full record

SynthesisSchizophrenia bulletin2015

Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.

Paolo Fusar-Poli, Evangelos Papanastasiou, Daniel Stahl, Matteo Rocchetti, William Carpenter, Sukhwinder Shergill, Philip McGuire

Erratum issued 3 registry-linked trialsAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Schizophrenia bulletin, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 3 registered trials, which are not on this map. Cited by 325 papers, 21 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
325citing papers in PubMed, 21 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04545294 nacompletednot on this mapstarted 2019, after this paper: background citation

Online Left-hemispheric Frontoparietal Theta In-phase tACS During Working Memory Training in Schizophrenia Patients: A Pilot Randomized Double-blind, Sham-controlled Study of the Effects on Negative Symptoms

TypeinterventionalSponsorTri-Service General Hospital (TSGH)Ran2019 to 2020Enrolled36ConditionsSchizophrenia, Schizoaffective Disorder, Negative Symptoms, Working Memory TrainingArmsTheta tACS
NCT06127004 narecruitingnot on this mapstarted 2024, after this paper: background citation

Metacognitive Training for Negative Symptoms (MCT Minus)

TypeinterventionalSponsorSormland County Council, SwedenRan2024 to 2032Enrolled90ConditionsNegative Symptoms in SchizophreniaArmsMetacognitive Training for Negative Symptoms (MCT), Supportive Counselling
NCT06588270 narecruitingnot on this mapstarted 2022, after this paper: background citation

Effect of Virtual Reality-based Therapy on Negative Symptoms in People with Schizophrenia: Study Protocol for a Randomized Controlled Trial

TypeinterventionalSponsorHospital de la Florida Dra. Eloiza DiazRan2022 to 2025Enrolled102ConditionsSchizophreniaArmsVirtual Reality Therapy for the Negative Symptoms of Schizophrenia, Sham- VR
3 · Its place in the literature

Who cites it

325 citing papers in PubMed, 21 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Humour-based interventions for people with schizophrenia.The Cochrane database of systematic reviews · 2021
    Pooled it

265 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Paolo Fusar-PoliDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience King's College London, London, UK; OASIS team, South London and the Maudsley NHS Foundation Trust, London, UK;
Evangelos PapanastasiouDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience King's College London, London, UK; evangelos.e.papanastasiou@kcl.ac.uk.
Daniel StahlDepartment of Biostatistics, Institute of Psychiatry, Psychology and Neuroscience King's College London, London, UK;
Matteo RocchettiDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience King's College London, London, UK; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy;
William CarpenterDepartment of Psychiatry and Pharmacology, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD.
Sukhwinder ShergillDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience King's College London, London, UK;
Philip McGuireDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience King's College London, London, UK; OASIS team, South London and the Maudsley NHS Foundation Trust, London, UK;

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesExisting treatments for schizophrenia can improve positive symptoms, but it is unclear if they have any impact on negative symptoms. This meta-analysis was conducted to assess the efficacy of available treatments for negative symptoms in schizophrenia.

methodsAll randomized-controlled trials of interventions for negative symptoms in schizophrenia until December 2013 were retrieved; 168 unique and independent placebo-controlled trials were used. Negative symptom scores at baseline and follow-up, duration of illness, doses of medication, type of interventions, and sample demographics were extracted. Heterogeneity was addressed with the I (2) and Q statistic. Standardized mean difference in values of the Negative Symptom Rating Scale used in each study was calculated as the main outcome measure.

results6503 patients in the treatment arm and 5815 patients in the placebo arm were included. No evidence of publication biases found. Most treatments reduced negative symptoms at follow-up relative to placebo: second-generation antipsychotics: -0.579 (-0.755 to -0.404); antidepressants: -0.349 (-0.551 to -0.146); combinations of pharmacological agents: -0.518 (-0.757 to -0.279); glutamatergic medications: -0.289 (-0.478 to -0.1); psychological interventions: -0.396 (-0.563 to -0.229). No significant effect was found for first-generation antipsychotics: -0.531 (-1.104 to 0.041) and brain stimulation: -0.228 (-0.775 to 0.319). Effects of most treatments were not clinically meaningful as measured on Clinical Global Impression Severity Scale. CONCLUSIONS AND RELEVANCE: Although some statistically significant effects on negative symptoms were evident, none reached the threshold for clinically significant improvement.

Indexed as

HumansOutcome Assessment, Health CareRandomized Controlled Trials as TopicSchizophreniaantipsychoticsnegative symptomspsychosisschizophreniatreatment

Identifiers

PMID25528757
PMCPMC4466178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.